Core Viewpoint - The company, 泰恩康, is forecasting a significant decline in net profit for 2025, with estimates ranging from 25 million to 35 million yuan, representing a year-on-year decrease of 67.66% to 76.90% [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 25 million and 35 million yuan, a decrease of 67.66% to 76.90% year-on-year [1] - The forecasted net profit excluding non-recurring gains and losses is estimated to be between 27 million and 37 million yuan, reflecting a year-on-year decline of 65.11% to 74.54% [1] Group 2: Business Segment Analysis - The company's core business in sexual health has experienced a decline in sales revenue due to increased competition and a growing number of competing products, although there are signs of a gradual market recovery [1] - The product "爱廷玖" (Dapoxetine Hydrochloride Tablets) has a strong brand presence, and the company plans to enhance brand promotion to boost sales [1] - The launch of the new product "爱廷列" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1] Group 3: Operational Challenges - The core product "和胃整肠丸" (Hewei Zhengchang Wan) has seen a decline in sales due to insufficient production capacity from Thai manufacturers and delays in imports [1] - The company is actively working on the registration and approval process for "和胃整肠丸" in China to address production capacity bottlenecks [1] Group 4: Investment and Expenses - In 2025, the company plans to increase investment in research and development while also intensifying brand promotion efforts, which will lead to higher sales expenses and compress profit margins [1]
泰恩康：2025年全年净利润同比预减67.66%—76.90%